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Background: The HIV-1 accessory factor Vif is necessary for efficient viral infection in non-permissive cells. Vif
antagonizes the antiviral activity of human cytidine deaminase APOBEC3 proteins that confer the non-permissive
phenotype by tethering them (APOBEC3DE/3F/3G) to the Vif-CBF-β-ElonginB-ElonginC-Cullin5-Rbx (Vif-CBF-β-EloB-
EloC-Cul5-Rbx) E3 complex to induce their proteasomal degradation. EloB and EloC were initially reported as
positive regulatory subunits of the Elongin (SIII) complex. Thereafter, EloB and EloC were found to be components
of Cul-E3 complexes, contributing to proteasomal degradation of specific substrates. CBF-β is a newly identified key
regulator of Vif function, and more information is needed to further clarify its regulatory mechanism. Here, we
comprehensively investigated the functions of EloB (together with EloC) in the Vif-CBF-β-Cul5 E3 ligase complex.
Results: The results revealed that: (1) EloB (and EloC) positively affected the recruitment of CBF-β to Vif. Both
knockdown of endogenous EloB and over-expression of its mutant with a 34-residue deletion in the COOH-terminal
tail (EloBΔC34/EBΔC34) impaired the Vif-CBF-β interaction. (2) Introduction of both the Vif SLQ→ AAA mutant
(VifΔSLQ, which dramatically impairs Vif-EloB-EloC binding) and the Vif PPL→ AAA mutant (VifΔPPL, which is
thought to reduce Vif-EloB binding) could reduce CBF-β binding. (3) EloB-EloC but not CBF-β could greatly enhance
the folding of full-length Vif in Escherichia coli. (4) The over-expression of EloB or the N-terminal ubiquitin-like (UbL)
domain of EloB could significantly improve the stability of Vif/VifΔSLQ/VifΔPPL through the region between
residues 9 and 14.
Conclusion: Our results indicate that the Vif interaction with EloB-EloC may contribute to recruitment of CBF-β to
Vif, demonstrating that the EloB C-teminus may play a role in improving Vif function and that the over-expression
of EloB results in Vif stabilization.
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The human immunodeficiency virus type 1/acquired im-
munodeficiency syndrome (HIV‑1/AIDS) epidemic is a
global health concern. Vif, as an accessory gene of HIV-1,
plays pivotal roles in both the early and late steps of the
HIV-1 life cycle [1-3]. Vif is necessary for efficient viral rep-
lication in non-permissive cell lines [4], and APOBEC3* Correspondence: weikong@jlu.edu.cn; xianghui@jlu.edu.cn
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reproduction in any medium, provided the orhost proteins (APOBEC3B, APOBEC3DE, APOBEC3G
and APOBEC3F) [5] are sufficient to confer the non-
permissive phenotype [6-11]. They possess strong antiviral
activities based on deamination of retroviral complemen-
tary DNA [12]. Vif counteracts the anti-HIV activity mainly
by recruiting the APOBEC3 proteins (APOBEC3DE,
APOBEC3G and APOBEC3F) [5], the transcription cofac-
tor CBF-β and EloB-EloC to the Cul5-Rbx complex,
thereby forming an E3 ubiquitin ligase and ultimately indu-
cing the proteasomal degradation of these antiviral host
proteins [10,13-17].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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prerequisite for Vif to neutralize APOBEC3 proteins, the
functional domains that Vif utilizes to recruit the E3 com-
plex have been well studied [18,19]. The N-terminal re-
gion of Vif contains the main sites involved in binding
of CBF-β and APOBEC3 proteins [17,20-25], while its
C-terminal domain contains a so-called SOCS-box motif,
which is responsible for binding to the EloB-EloC complex
[26-28], and a conserved HCCH zinc coordination site
that mediates selective binding to Cul5 [29-32]. Every
component of the Vif-Cul5 E3 ligase is indispensable for
degradation of APOBEC3 proteins. Vif acts as a substrate
adaptor molecule to bridge APOBEC3G (A3G) with the
Cul5 E3 ligase [13], and the newly found factor CBF-β is
reported to be a unique regulator of Vif-Cul5 E3 ligase by
promoting folding of Vif [25,33-36]. EloB and EloC are
also known as regulatory subunits, whereas Cul5 functions
as a scaffold protein [13].
EloB and EloC are two ubiquitous proteins that form a
heterodimer complex. They were originally found in the
Elongin (SIII) complex, which was proposed to contain
three subunits: EloA, EloB and EloC [37,38]. EloA is
known as a positive transcriptional elongation factor of
RNA polymerase II, whereas EloB and EloC act as positive
regulators of EloA [37,38]. Soon afterward, EloB and EloC
were identified in many cullin-RING ubiquitin ligase com-
plexes [13,39-42], forming the cullin E3 core together with
cullin family proteins Cul2/Cul5 and a RING finger pro-
tein Rbx [43]. In these E3 ligase complexes, EloB-EloC
binds to substrate-targeting subunits via a conserved motif
called the BC-box [42-44] in order to mediate poly-
ubiquitination and ultimately proteasomal degradation
of the targeted substrates. These substrate-binding pro-
teins, which are characterized by the SOCS-box motif
containing the N-terminal BC-box sequence [42-44], typ-
ically include cellular proteins such as von Hippel-Lindau
(VHL) tumor suppressor [40,45] and the suppressor
of cytokine signaling (SOCS) [41,42,46], with correspond-
ing substrates HIF-1α [40,45] and Janus kinases (JAKs)
[41,42,46]. The substrate-binding proteins may also be
viral proteins, such as adenovirus E4orf6 [39] and HIV-1
Vif [13], which target the substrates p53 [39] and the well-
known APOBEC3 proteins [13], respectively.
EloB is a highly conserved cellular factor in humans,
rats, Drosophila melanogaster and Caenorhabditis elegans
[47]. As a member of the third class of ubiquitin family
proteins, it is a 118-amino acid protein composed of an
84-amino acid N-terminal (ubiquitin-like) UbL domain
and a 34-amino acid COOH-terminal tail, both of which
are highly conserved [47,48]. The EloB UbL domain is ne-
cessary and sufficient for binding to EloC [47,48], whereas
its C-terminal tail has been reported to interact with
SOCS2 and SOCS4 proteins, significantly stabilizing the
SOCS2 E3 complex and assisting folding of the SOCS4protein [49,50]. In the Vif-CBF-β-Cul5 E3 complex, the
C-terminus of EloB is known to bind to the PPLP motif of
Vif, but without an ascribed function as yet [26].
In this study, we demonstrated that the interactions
between Vif and EloB-EloC are important for CBF-β re-
cruitment to Vif. Both knockdown of endogenous EloB (to-
gether with EloC) and over-expression of EloBΔC34, an
EloB mutant with a 34-residue deletion in the COOH-
terminal tail, impaired the Vif-CBF-β interaction and stabi-
lized the A3G level. The interaction with EloB-EloC, but
not CBF-β, was shown to greatly increase the solubility of
full-length Vif in Escherichia coli, and in cells, both the
introduction of the VifΔSLQ mutant, which dramatically
impairs Vif-EloB-EloC binding, and that of the VifΔPPL
mutant, which is considered to reduce Vif-EloB binding,
were found to impair Vif-CBF-β binding [33,36]. Moreover,
we showed that over-expression of EloB or EloBΔC34
could significantly prevent degradation of Vif/VifΔSLQ/
VifΔPPL, indicating that the EloB N-terminal UbL domain
may enhance the stability of Vif in an unknown manner.
We also found that EloB stabilized Vif mainly through the
same region (between residues 9 and 14) by which it
interacted with EloC. Overall, our study is helpful in fur-
ther understanding the interactions among components of
the Vif-CBF-β-Cul5 E3 complex, demonstrates that the
C-terminus of EloB, which is not required for EloC binding
and degradation of P53, plays a role in improving Vif
function and expands the diversity of functions of the UbL
protein EloB.
Results
Knockdown of endogenous EloB expression impairs
Vif-induced A3G degradation and decreases HIV-1 virion
infectivity
CBF-β and EloB-EloC are reported to regulate Vif function
by promoting folding of different domains of Vif
[25,28,34,51,52], both of which affect Cul5 binding to Vif
[13,36], while knockdown of CBF-β does not impair EloB-
EloC binding to Vif [36]. In order to further study the
events in the assembly of the Vif-CBF-β-Cul5 complex, we
attempted, but failed, to obtain a complete knockdown of
EloC (data not shown), similar to the results obtained
by Hwang et al. [53]. Therefore, we designed three
EloB-specific small interfering RNAs (siRNAs), designated
siEB1, 2 and 3, to knock down endogenous EloB expres-
sion. Down-regulation of EloB expression in 293 T cells by
the three siRNAs was confirmed by Western blot analysis
72 h after transfection (Figure 1A). The EloB protein band
intensities in the immunoblot were quantified using
Bandscan software (Glyko, Novato, CA) and normalized
to tubulin. SiEB1 caused an approximately 60% decrease,
whereas siEB2 caused a modest decrease and siEB3
showed nearly no effect, in EloB expression compared
with cells transfected with the negative control siRNA
Figure 1 RNAi-mediated silencing of endogenous EloB expression impairs Vif functions. (A) 293 T cells were seeded in 6-well plates at
0.8 × 106 cells per well just prior to transfection with siRNAs at a final concentration of 20 nM. The cells were harvested at 72 h post-transfection,
and EloB protein expression was analyzed by Western blot. Mock, cells treated with Hiperfect transfection reagent only; siNC, cells transfected
with AllStars Negative Control siRNA; siEB1-3, cells transfected with EloB-siRNA1-3. Band intensities were quantified using Bandscan software,
normalized to tubulin and expressed as percentages of the mock value. (B) 293 T cells transfected with siRNAs were harvested at 72 h post-
transfection and analyzed by qRT-PCR for EloB mRNA levels normalized to β-actin mRNA. Fold changes in EloB gene expression relative to that
of the mock control are shown. (C) At 24 h after siRNA treatment, 293 T cells (siRNA-treated cells were grown in 25 cm2 flasks to about 80%
confluency) were co-transfected with 450 ng of VR-A3G-HA, 3.5 μg of NL4-3ΔVif, and 1.2 μg of VR-Vif or VR1012. After 48 h of transfection, cells
were examined for A3G expression (lanes 1–3, control siRNA treated cells; lanes 4–6, EloB siRNA treated cells), and corresponding supernatants
were used in (D) and (E). (D) Pelleted virions obtained from (C) were examined for A3G–HA virion packaging. (E) Relative infectivity of viruses
obtained from (C) was assessed by the MAGI assay, with the infectivity of viruses produced from cells co-transfected with NL4-3ΔVif and VR-Vif in
the presence of control siRNA was set to 100%. Virus input was normalized according to the p24 level. Error bars in (B) represent standard
deviations from three independent experiments and in (E) from triplicate wells.
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Hiperfect transfection reagent only) (Figure 1A). The silen-
cing efficiency of the most effective EloB siRNA, siEB1, in
293 T cells was further validated by quantitative real-time
PCR (qRT-PCR), which showed an approximately 70% de-
crease in EloB mRNA (Figure 1B). Expression levels of
EloB mRNA and proteins in these assays were normalized
to the expression of β-actin in the corresponding samples.
Based on these results, siEB1 was utilized in all subsequent
experiments to transiently knock down EloB.
To determine whether EloB knockdown would result in
impairment of HIV-1 Vif function, we co-transfected
pNL4-3ΔVif and VR-Vif (without a tag) or empty plasmid
VR1012 in the presence of siEB1 or siNC. In the siNC-
transfected 293 T cells, the over-expressed Vif could effi-
ciently reduce the intracellular level of A3G (Figure 1C,
lane 3) when compared to the no Vif control (lane 2). Si-
lencing of endogenous EloB (Figure 1C, lanes 4–6) indeed
impaired Vif-mediated depletion of A3G, even in the pres-
ence of other HIV-1 proteins (Figure 1C, lane 6). This
result confirmed that EloB was required for the Vif-
mediated destruction of A3G as reported previously
[13,27] (Figure 1C, compare lanes 2, 3 to lanes 5, 6).Incorporation of A3G into HIV-1 virions is a pre-
requisite for its antiviral activity [14,54]. Vif circumvents
this antiviral activity by depleting intracellular stores of
A3G, thereby inducing virion exclusion of A3G. Consist-
ent with other studies [13,33], we found that A3G could
be incorporated into HIV-1 virions in the absence of Vif
(Figure 1D, lane 2), and when Vif was present, the
intravirion packaging of A3G was prevented in siNC-
transfected cells (Figure 1D, lane 3). Nevertheless, when
using siEB1-transfected cells in which endogenous EloB
expression was efficiently suppressed as virus-producing
cells, the ability of Vif to block the incorporation of A3G
into the budding virus was impaired (Figure 1D, com-
pare lanes 3 and 6). Silencing of endogenous EloB could
also impair the ability of Vif to neutralize the antiviral
activity of A3G (Figure 1E).
EloB is critical for the interaction between Vif and CBF-β
Because it was recently reported that EloB interacts with
the PPLP motif of Vif which is necessary for A3G bind-
ing [26,55], we considered whether knockdown of en-
dogenous EloB expression would interfere with the
interaction between A3G and Vif. To determine whether
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expressing untagged Vif or empty vector VR1012 was
co-transfected with VR-A3G-HA into 293 T cells for a
co-immunoprecipitation assay. The transfected cells
were treated with the proteasome inhibitor MG132
(10 μM) for 12 h before harvesting. Vif was efficiently
co-immunoprecipitated with A3G–HA by the anti-HA
antibody both in siNC-transfected cells and in siEB1-
transfected cells (Figure 2A, compare lanes 6 and 8),
showing that the reduction of EloB expression had no
effect on the Vif-A3G interaction. Therefore, we con-
cluded that EloB may not regulate substrate recognition
of Vif.
To explore if silencing of EloB could affect the expres-
sion of E3 components, or their interactions with Vif,
we transfected a vector expressing HA-tagged Vif into
293 T cells treated with siNC or siEB1, followed by co-
immunoprecipitation. Indeed, expression levels of Cul5
and CBF-β were not affected by silencing of endogenous
EloB expression (Figure 2B, compare lanes 1, 2 to lanes
3, 4). However, a significant decrease in CBF-β binding
to Vif-HA was observed when EloB was silenced com-
pared to the siNC-treated cells (Figure 2B, compare
lanes 6 and 8). It is reasonable that the levels of EloC
were greatly reduced in siEB1-transfected cells, which is
consistent with the results obtained by Hwang et al.Figure 2 EloB is critical for the interaction between Vif and CBF-β. (A)
(106) were transfected with the indicated siRNAs. At 24 h after siRNA transf
A3G-HA or VR1012. The cells were treated with MG132 (10 μM) for 12 h be
anti-HA antibody, followed by SDS–PAGE and immunoblot analysis. (B) Elo
SiRNA-treated cells (106) were transfected with 2.5 μg of VR-Vif-HA or VR10
followed by SDS–PAGE and immunoblot analysis. (C) Endogenous CBF-β c
T cells (106) were transfected with 2.5 μg of VR-Vif-HA or VR-EloB-HA or VR1
followed by SDS–PAGE and immunoblot analysis. (D) CBF-β, EloB (EB) and
293 T cells (106) were transfected with 2 μg of VR-Vif-Myc, 2.5 μg VR-Vif SLQ
Myc antibody, followed by SDS–PAGE and immunoblot analysis. All results[53], as EloB is known to stabilize EloC and form an ob-
ligate heterodimer with EloC [13,38-42]. It was not sur-
prising to find that the interaction between Cul5 and
Vif–HA was significantly disrupted in siEB1-transfected
cells, since failures of both CBF-β and EloB-EloC in
binding to Vif have been reported to block the Vif-Cul5
interaction [27,33]. The results indicated that EloB may
affect the function of Vif by influencing assembly of the
Vif-Cul5 E3 complex. However, the remaining question
to be resolved in our study is whether these effects are
caused by the absence of EloB or EloC (or both).
Zhang et al. had reported that CBF-β does not inter-
act with Cul5 or EloB/C [33]. To reconfirm that there
was no direct interaction between EloB and CBF-β, vec-
tors expressing EloB or Vif were transfected into 293 T
cells. Both proteins were fused to an HA epitope at their
C-terminus, and their expression levels were observed
in 293 T cells (Figure 2C, lanes 2, 3). Both EloB and Vif
could be immunoprecipitated by the anti-HA antibody
(Figure 2C, lanes 5, 6), and CBF-β was efficiently co-
immunoprecipitated with Vif (Figure 2C, lane 5). In-
deed, CBF-β was not co-immunoprecipitated with EloB
(Figure 2C, lane 6).
After determining that silencing of EloB expression
could impair binding of Vif to CBF-β, we postulated
that the interaction of Vif with EloB (and EloC) isEloB did not affect the interaction between Vif and A3G. 293 T cells
ection, cells were co-transfected with 2.5 μg of VR-Vif and 1 μg of VR-
fore harvesting. Cell lysates were co-immunoprecipitated (Co-IP) with
B silencing impaired both the Vif-CBF-β and the Vif-Cul5 interactions.
12. Cell lysates were immunoprecipitated (IP) with anti-HA antibody,
o-immunoprecipitated with Vif–HA but not EloB–HA (EB-HA). 293
012. Cell lysates were immunoprecipitated with an anti-HA antibody,
EloC (EC) co-immunoprecipitated with Vif–Myc but not Vif SLQ–Myc.
-Myc or VR1012. Cell lysates were immunoprecipitated with an anti-
are representative of three independent experiments.
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esis, we transfected vectors expressing Vif or Vif-SLQ
into 293 T cells. Both of these expressed proteins were
tagged with a C-terminal Myc epitope. Vif-SLQ con-
tains mutations of critical residues in the Vif SOCS box
(SLQ to AAA), which can significantly disrupt the in-
teraction of mutant Vif with EloB-EloC. The results
showed that Vif and Vif-SLQ were expressed at compar-
able levels (Figure 2D, lanes 2 and 3), and both of these
proteins could be immunoprecipitated by the anti-Myc
antibody (Figure 2D, lanes 5 and 6). CBF-β could be ef-
ficiently co-immunoprecipitated with Vif, but it showed
almost no interaction with Vif-SLQ (Figure 2D, compare
lanes 5 and 6). This result indicated that the Vif-EloB-
EloC interaction is important for Vif-CBF-β binding.Figure 3 EloB significantly stabilizes Vif. 293 T cells (106) were cotransfe
with co-transfection of 1 μg VR-EloB (+ Elongin B), 1 μg VR-EloC (+ Elongin
treated with 100 μg/ml CHX 36 h after transfection and harvested at the in
was performed using an anti-Vif antibody. EloB-Myc (EB-Myc) and EloC-HA
panels). (A) Positions of Vif are indicated on the right (upper). (B) Positions
intensities of Vif in (A) were quantified using Bandscan software, normalize
value at 0 h (set to 100%) and graphically represented. (D) Quantification o
representative of three independent experiments. Error bars represent ± SDOver-expression of EloB prevents significant degradation
of Vif
HIV-1 Vif itself has been reported to undergo rapid
proteasomal degradation by MDM2 and other E3 ligases
[56,57]. As VHL is known to protect against proteasomal
degradation by binding with EloB-EloC [58], we specu-
lated that the binding of EloB (and EloC) to Vif may
affect the stability of Vif . To test this hypothesis and to
assess the effect of EloB and EloC binding on Vif stabil-
ity, we transiently co-transfected the untagged Vif or
VifΔSLQ expression vector into 293 T cells in the ab-
sence or presence of EloB or EloC expression vector or
both and examined the stability of Vif/Vif-SLQ mo-
lecules using the cycloheximide (CHX) stability assay
(Figure 3). To determine relative Vif expression levels,cted with 1 μg of VR-Vif or VR-Vif-SLQ, either without (- Elongin BC) or
C), or both 1 μg VR-EloB and 1 μg VR-EloC (+ Elongin BC). Cells were
dicated time points. Western blot analysis of Vif/Vif-SLQ (upper panels)
(EC-HA) were detected with appropriate epitope-tag antibodies (lower
of Vif-SLQ are indicated on the right (upper). (C) Individual band
d to the quantity of tubulin bands, expressed as percentages of the
f Vif-SLQ bands in (B) was performed as described in (C). All results are
(n = 3).
Wang et al. Retrovirology 2013, 10:94 Page 6 of 16
http://www.retrovirology.com/content/10/1/94band intensities detected in this assay were scanned using
the Glyko Bandscan software and normalized to tubulin.
As previously reported [56], over-expressed wild-type Vif
and Vif-SLQ were both rapidly degraded in the absence of
EloB-EloC (Figure 3). Co-transfection of both EloB and
EloC could increase Vif stability but showed almost no ef-
fect on Vif-SLQ degradation (Figure 3). These results
demonstrated that EloB-EloC binding could stabilize Vif.
Strikingly, co-transfection of EloB and Vif/Vif-SLQ mark-
edly stabilized both wild-type Vif and Vif-SLQ to a greater
extent than did co-transfection of EloB-EloC, whereas
co-transfection of EloC and Vif/Vif-SLQ only slightly
increased the stability of wild-type Vif and Vif-SLQ
(Figure 3).
The finding above (Figure 3) was different from an-
other study showing that EloB has almost no effect on
VHL stability [58], which suggests that EloB may have
more functions in the Vif-Cul5 E3 complex than it does
in the VHL-Cul2 E3 complex. Additionally, the results
seemed to be contradictory to those in Figure 1C and
Figure 2A. That is, EloB could stabilize the Vif protein in
our experiments, but when EloB expression was silenced
by siRNA, the levels of Vif protein were not affected in
Figure 2A, while they were increased in Figure 1C. We
presumed that EloB may have prevented the degradation
of Vif through the same sites by which it interacted with
EloC, and thus only over-expression of EloB (free EloB)
could result in Vif stabilization. In other words, when
EloB was co-expressed with EloC, it may have preferen-
tially formed an obligate heterodimer with EloC and lost
the ability to significantly stabilize Vif. Therefore, the en-
dogenous EloB in the cell could not stabilize Vif in the
presence of endogenous EloC and would not cause Vif
downregulation when it was knocked down. Moreover,
as it is generally believed that A3G and Vif are both de-
graded by the EloB-EloC-Cul5 E3 ligase [15,59-61], it
may be reasonable that the decrease of EloB (and EloC)
protein level which would hinder the formation of the
E3 complex could allow both Vif and A3G to escape
from degradation (Figure 1C). Therefore, it is not con-
tradictory to find that EloB over-expression stabilizes Vif
and that down-regulation of endogenous EloB also sta-
bilizes Vif. The discrepancy between Figure 1C and
Figure 2A may be due to the addition of MG132 at 12 h
before cell harvesting in Figure 2A.
We also observed that the Vif-SLQ mutant did not
have a longer half-life than the wild-type Vif protein,
which seemed to be paradoxical if Vif was degraded by
the EloB-EloC-Cul5 E3 ligase [15,59-61]. However, it
was reported that coexpression of A3G promotes
polyubiquitination and proteasomal degradation of Vif
[61]. That is, in the absence of A3G, the EloB-EloC-Cul5
E3 ligase would have little effect on the half-life of Vif
[61]. Furthermore, Vif was also reported to be degradedby the MDM2 E3 ligase and other unknown mecha-
nisms [57]. Thus, it was reasonable that the Vif-SLQ
mutant showed a similar half-life to that of the wild-type
Vif protein. Moreover, without assistance of EloB-EloC,
the Vif-SLQ mutant may fold differently than the wild-
type Vif, which may also affect its stability.
Dissecting the interaction network of Vif-CBF-β-EloB-EloC
complex subunits by co-expression in E. coli
Co-expression of subunits of multiprotein complexes in
E. coli has been used for interaction analysis [51,62].
Successful over-expression of soluble proteins is thought
to be achieved if the subunit proteins are co-expressed
with their cognate partners [63-65]. In other words, sub-
units of a complex may fold incorrectly when expressed
individually, but they may mutually enhance the folding
of co-expressed proteins, thereby preventing aggregation
of nascent unfolded proteins and leading to increase
solubility. To co-express components of the Vif-CBF-β-
EloB-EloC complex, we used the pST39 polycistronic
expression system, which allowed simultaneous over-
expression of the subunits [63]. To rule out potential
effects of epitope tags on Vif solubility, all subunits were
expressed untagged. We found that the full-length Vif
protein (residues 1–192) was predominantly insoluble
(>90%) as determined by both Coomassie staining and
immunoblotting with a Vif-specific antibody (Figure 4).
Co-expression with full-length CBF-β (isoform 1, resi-
dues 1-182), EloB or EloC could not substantially im-
prove the solubility of Vif (Figure 4). This result
indicated that CBF-β, EloB and EloC individually may
not be able to interact with Vif in the absence of other
E3 components. Co-expression of Vif with both CBF-β
and EloB did not improve its solubility when compared
with that when co-expressed with EloB only; likewise,
co-expression of Vif with both CBF-β and EloC also did
not increase its solubility compared with that when co-
expressed with EloC alone (Figure 4). These results indi-
cated that CBF-β could not co-fold well with Vif even in
the presence of EloB or EloC. However, when Vif was
co-expressed with both EloB and EloC, its solubility was
significantly increased and was modestly improved by
co-expression with CBF-β (Figure 4). The solubility of
CBF-β also could only be improved by co-expression
with Vif-EloB-EloC. These results indicated that the
co-folding of CBF-β and Vif may be dependent on the
interaction of Vif with both EloB and EloC in vitro,
which was basically consistent with results of our co-
immunoprecipitation analysis (Figure 2B, D).
This experiment had some similarities to an analysis
performed by Zhou et al. [51], in which there seemed to
be a discrepancy regarding the effect of CBF-β on Vif solu-
bility. The authors used a truncated His-tagged CBF-β
(residues 1–140), instead of an untagged full-length CBF-β
Figure 4 Soluble Vif and CBF-β proteins can be efficiently produced only in the presence of EloB/C. E. coli BL21 (DE3) cells containing
appropriate pST39 constructs were induced, harvested, homogenized by sonication and then clarified by centrifugation. For solubility analysis, the
supernatant and the pellet were subjected to SDS–PAGE. All proteins were untagged. (A) Solubility of Vif, expressed alone or co-expressed with
CBF-β, EloB, EloC, CBF-β + EloB, CBF-β + EloC, EloB + EloC or CBF-β + EloB + EloC, was determined by visualization with Coomassie staining. Tot,
total cell lysate; S, supernatant; P, pellet. (B) Fractions in (A) were visualized by immunoblotting using appropriate antibodies. (C) Quantification of
band intensities of Vif in (B). All experiments were repeated three times.
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Vif solubility. Since the notion is generally accepted that
the solubility of an over-expressed recombinant protein in
E. coli can be greatly affected by slightly changing the
amino acid sequence at its N- or C-terminus [66-69], it
was reasonable that our results differed from each other.
Zhou et al. also reported that the purified Vif-CBFβ140
complexes were aggregated and unstable [51]. In their
study, the Vif-CBFβ140 complexes precipitated quickly at
low temperatures, with the Vif protein precipitating even
faster than the CBFβ140 protein, while the Vif-CBFβ140-
EloB-EloC complexes were much more stable [51]. Their
results indicated that the Vif-CBFβ140 complexes may be
misfolded in the absence of EloB-EloC in E. coli, and CBF-
β could co-fold well with Vif when they were coexpressed
with EloB-EloC, supporting our data.
Over-expression of EloB mutant with a 34-residue
deletion in the COOH-terminal tail blocks Vif-induced A3G
degradation
Several lines of evidence have indicated that the Vif-
binding motif is located in the C-terminal tail of the EloB
protein, whereas residues involved in the contact with
EloC are dispersed throughout the EloB primary sequence
in both the N-terminal UbL domain and the C-terminal
region (indicated in Figure 5A) [26,48,70,71]. The con-
served EloB N-terminal was named the UbL domain be-
cause it bears marked sequence similarity to ubiquitin
[48], and its tertiary structure (shown in red, PDB
code: 3DCG) is strikingly similar to that of ubiquitin
(shown in green, PDB code: 1UBQ) when aligned using
software PyMol (http://pymol.org/, Figure 5B) [28,72].The conserved UbL domain is reported to be necessary
and sufficient for the EloB-EloC interaction [47,48],
the function of which has been well-studied, but the
C-terminal region of EloB is also highly conserved. The re-
cently discovered interaction between the C-terminus of
EloB and Vif implied that there may be as yet undiscov-
ered functions of EloB within the Vif-Cul5 E3 complex.
To explore the possible functions of the EloB C-terminal
domain, we constructed a mutant with a deletion of 34
amino acids in the C-terminal tail, EBΔC34 (Figure 5A),
which was untagged to rule out potential effects of an epi-
tope tag on EB function. To determine whether the EloB
C-terminal deletion would affect Vif function, 293 T cells
were co-transfected with pNL4-3ΔVif and VR-Vif (without
a tag) or empty plasmid VR1012 in the presence of
VR-EloBΔC34 or VR-EloB. The untagged EBΔC34 and
wild-type EB were detected by immunoblotting with an
anti-EloB polyclonal antibody, which was raised using a
synthetic peptide derived from the internal sequence (resi-
dues 20–48) of human EloB (Abcam, NP_009039.1). The
Vif-mediated depletion of A3G was impaired by over-
expression of EBΔC34 (Figure 5C) and this impairment
was dose-dependent (Figure 5E), whereas wild-type EB had
no effect of impairment (Figure 5C, D). These results indi-
cated that the C-terminal tail of EloB was important for
EloB to improve Vif function.
Interestingly, the co-expression of EBΔC34 strikingly in-
creased the intracellular protein level of Vif, even at a low
dose (Figure 5C, E), indicating a possible stabilization of
Vif by EBΔC34. The over-expression of EBΔC34 did not
affect the endogenous expression of EloC (Figure 6B), rul-
ing out the possibility that EloB regulates Vif function
Figure 5 The 34-amino acid C-terminal tail of EloB is required for regulation of Vif function. (A) Schematic representations of functional
domains of EloB based on existing evidence and of the EloB C-terminal deletion mutant used in this study. (B) Structural alignment of EloB (red)
and ubiquitin (green). The tertiary structure of the EloB UbL domain bears striking similarity to that of ubiquitin, whereas the tertiary structure of
the EloB C-terminal tail was not found in that of ubiquitin. (C) 293 T cells grown in 25 cm2 flasks to about 80% confluency were co-transfected
with 450 ng of VR-A3G-HA, 3.5 μg of NL4-3ΔVif, and 1.2 μg of VR-Vif or VR1012 in the presence of 750 ng of wild-type EB (lanes 1–3) or 1.5 μg of
EBΔC34 (lanes 4–6). Cells were harvested 48 h after transfection and analyzed by Western blot. A3G expression was calculated relative to that
detected in the absence of both Vif and EBΔC34 (set to 100%). (D) 293 T cells (106) were co-transfected with 300 ng of VR-A3G-HA, 600 ng of VR-
Vif or VR1012 and increasing amounts of vectors expressing EB or VR1012 (150, 250 and 350 ng). Cells were harvested 48 h after transfection and
analyzed by Western blot. (E) 293 T cells (106) were co-transfected with 300 ng VR-A3G-HA, 600 ng VR-Vif or VR1012 and increasing amounts of vectors
expressing EBΔC34 or VR1012 (300, 500 and 700 ng). Cells were harvested 48 h after transfection and analyzed by Western blot. (F) 293 T cells (106)
were co-transfected with 7.5 ng VR-P53-HA and 1 μg VR-E4orf6-Myc or VR1012 in the presence of 750 ng of wild-type EB (lanes 1–2) or 1.5 μg of
EBΔC34 (lanes 3–4). The cells were harvested 48 h post-transfection and analyzed by Western blotting. All experiments were repeated three times.
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the question posed above.
To determine whether over-expression of the dominant-
negative mutant EBΔC34 is capable of blocking poly-
ubiquitination of all substrates, we employed the
adenovirus protein E4orf6 because it contains a Vif-like
BC-box by which it assembles with Cul5-EloB-EloC E3
complex, similar to Vif, to regulate p53 [73]. 293 T cellswere co-transfected with VR-P53-HA and E4orf6-pCMV6.9
or empty plasmid VR1012 in the presence of VR-
EloBΔC34 or VR-EloB. The harvested cells were analyzed
by Western blotting with anti-P53, anti-myc, anti-EloB
and anti-ribosomal antibodies. According to the results,
the over-expression of EBΔC34 had almost no effect on
the E4orf6-mediated depletion of P53 (Figure 5F), even
when the amount of expression plasmid was increased
Figure 6 EloB promotes CBF-β binding to Vif mainly by its C-terminus. (A) Both Flag-tagged EB and EBΔC34 co-immunoprecipitated with
EC-HA. 293 T cells (106) were co-transfected with 1 μg of VR-EC-HA and 600 ng of VR-Flag-EB or 3 μg of VR-Flag-EBΔC34. Cell lysates were
immunoprecipitated with anti-HA antibody, followed by SDS–PAGE and analyzed by Western blotting with anti-HA, anti-Flag and anti-tubulin
antibodies. (B) Over-expression of Flag-tagged EBΔC34 impaired the interaction between Vif and CBF-β. 293 T cells (106) were transfected with 2 μg
of VR-Vif-HA and 400 ng of VR-Flag-EB-HA or 2 μg of VR-Flag-EBΔC34. Cell lysates were immunoprecipitated with an anti-HA antibody, followed by
SDS–PAGE and immunoblot analysis. (C) The PPL→ AAA mutation of Vif resulted in impaired CBF-β binding to Vif. 293 T cells (106) were transfected
with 800 ng of VR-Vif-HA or 3 μg of VR-VifΔPPL-HA or VR1012. Cell lysates were immunoprecipitated with an anti-HA antibody, followed by Western
blotting with anti-HA, anti-CBF-β, anti-EloB and anti-EloC antibodies. The result is representative of three independent experiments.
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may be specifically required for improving Vif function.
The interaction between the Vif PPLP motif and the
conserved 34-amino acid COOH-terminal tail of EloB plays
a role in promoting recruitment of CBF-β to the Vif-Cul5
E3 complex
Since the C-terminal tail of EloB also contains residues
that are involved in EloC binding [71] (Figure 5A), we fur-
ther examined whether EloBΔC34 could still interact with
EloC. 293 T cells were transfected with VR-EloC-HA and
VR-Flag-EloB or VR-Flag-EloBΔC34 to examine the in-
teraction between HA-tagged EloC and N-terminally
flag-tagged EloB or EloBΔC34. The cell lysates were
immunoprecipitated with an anti-HA antibody. We found
that both EloB and EloBΔC34 could be efficiently co-
immunoprecipitated with EloC-HA (Figure 6A), indicating
a similar ability to bind EloC. To explore whether EBΔC34
may influence Vif function by affecting assembly of the
Vif-Cul5 E3 complex as observed with EloB silencing, we
examined the interaction of Vif-HA with endogenous
CBF-β and EloC in the presence of VR-flag-EBΔC34 or
VR-flag-EB by co-immunoprecipitation analysis. The results
showed that the CBF-β binding to Vif was impaired by
over-expression of the N-terminally Flag-tagged EloBΔC34,
whereas the interaction of EloC with Vif was not apparently
affected (Figure 6B), indicating that the 34-amino acid
C-terminal tail of EloB may play a role in promoting the
recruitment of CBF-β to Vif. EloB/EloBΔC34 itself could
also be co-immunoprecipitated with Vif-HA (Figure 6B).
Since the C-terminus of EloB interacts with the PPLP
motif of Vif [26], we wondered whether the PPL→AAA
mutation of Vif could also result in impaired CBF-β
binding to Vif. To test this hypothesis, we transfected
vectors expressing Vif or VifΔPPL into 293 T cells. Both
of the expressed proteins were tagged with a C-terminalHA epitope. The results showed that both Vif and
VifΔPPL could be immunoprecipitated by the anti-HA
antibody (Figure 6C), but VifΔPPL appeared to be less
able to bind CBF-β (Figure 6C). This result indicated
that the C-terminus of EloB may affect Vif-CBF-β bind-
ing by interacting with the PPLP motif of Vif and indu-
cing its structural change.
EloB stabilizes Vif mainly through residues 9-14 within its
ubiquitin- homology domain
We had found that over-expression of EloB could
stabilize both wild-type Vif and Vif-SLQ. Since the over-
expression of EloBΔC34 could increase the intracellular
protein level of Vif (Figure 5), we postulated that the
UbL domain would be sufficient for EloB to stabilize Vif.
Therefore, we over-expressed untagged Vif and Vif-SLQ
by transient transfection of their expression vectors into
293 T cells in the absence or presence of EloB or
EloBΔC34 plasmids. The stabilities of Vif and Vif-SLQ
were assessed by the CHX stability assay. As expected,
EloBΔC34 over-expression could stabilize both wild-type
Vif and Vif-SLQ, even to a greater extent than with EloB
(Figure 7).
Since EloBΔC34, which had lost the PPLP Vif binding
motif, could still stabilize Vif [26], we postulated that the
stabilization of Vif by EloB might be independent of the
PPLP motif. To verify this hypothesis, we transiently
transfected vectors expressing VifΔPPL-HA in the ab-
sence or presence of EloBΔC34 into 293 T cells and
examined the stability of VifΔPPL-HA proteins. The re-
sults showed that VifΔPPL could also be significantly
stabilized by EloBΔC34 (Figure 7E, F).
As it is generally believed that stabilization should be
accompanied by an interaction, we examined the inter-
actions between over-expressed EloB and Vif-SLQ mu-
tants. Indeed, an interaction was found between EloB
Figure 7 EloB stabilizes Vif via the same region by which it interacts with EloC. (A, B) Vectors expressing untagged Vif (1 μg) or Vif-SLQ
(1 μg) were transiently transfected into 293 T cells (106), either without (-EB/EC) or with co-transfection of 1 μg of EloB (+EB) or 2 μg of EloBΔC34
(+EBΔC34). Cells were treated with CHX and harvested as described in Figure 3. (C, D) Quantification of Vif/Vif-SLQ bands in (A, B). (E) Vectors
expressing VifΔPPL-HA (1 μg) were transiently transfected into 293 T cells (106), either without (-EB/EC) or with co-transfection of 2 μg of
EloBΔC34 (+EBΔC34). Cells were treated with CHX and harvested. (F) Quantification of VifΔPPL-HA bands in (F). All results in (C, D, F) are
representative of three independent experiments. Error bars represent ± SD (n = 3). (G) 293 T cells (106) were co-transfected with 1 μg of
VR-EB-HA or VR-EB-Myc and 2.5 μg VR-Vif-SLQ or 1 μg VR-Vif. Cell lysates were co-immunoprecipitated with an anti-HA antibody, followed
by Western blotting with anti-HA, anti-EloB and anti-Vif antibodies. Results are representative of six independent experiments. (H)
Schematic representation of the deletion mutagenesis of the EloC binding domain of EloB. (I) 293 T cells (106) were transfected with 1 μg
of VR-Vif-SLQ, either without or with co-transfection of 1 μg VR-EloB-HA (+EB), VR-EloBΔ9-17-HA (+EBΔ9-17), VR-EloBΔI34-HA (+EBΔI34) or
VR-EloBΔ69-72-HA (+EBΔ69-72). Cells were treated with CHX and harvested. Vif-SLQ were detected with anti-Vif antibody, and EloB was
detected with an anti-HA antibody. Results are representative of three independent experiments. (J) 293 T cells (106) were transfected
with 1 μg of VR-Vif SLQ with co-transfection of 1 μg VR-EloBΔ9-11-HA (+EBΔ9-11), VR-EloBΔ12-14-HA (+EBΔ12-14) or VR-EloBΔ15-17-HA
(+EBΔ15-17). Cells were treated with CHX and harvested. Vif-SLQ and EloB was detected as described in (I). Results are representative of
three independent experiments.
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that between EloB and wild-type Vif (Figure 7G). The
Vif-PPL mutant was also able to interact with EloB-EloC
(Figure 6C). Therefore, EloB may stabilize Vif-SLQ and
Vif-PPL mutants also by binding to them.
In order to explore whether EloBΔC34 could stabilize
all SOCS proteins that form complexes with Cul5, we
examined the stability of the E4orf6 protein in the ab-
sence or presence of EloBΔC34. Unfortunately, the half-
life of E4orf6 is very long, and it was found by itself to
be very stable without over-expression of EloBΔC34
(data not shown). However, we observed that the proteinlevel of E4orf6 could be slightly down-regulated by over-
expression of EloBΔC34 (data not shown).
We have presumed that EloB prevented degradation of
Vif through the same sites by which it interacted with
EloC. To verify this hypothesis, we constructed three
mutants, VR-EBΔ9-17-HA, VR-EBΔI34-HA and VR-
EBΔ69-72-HA, each of which contained a deletion in a
region in the EloB UbL domain involved in the contact
with EloC (Figure 7H), in order to examine their effects
on Vif stability. We found that the EBΔ9-17 mutant al-
most lost the ability to stabilize Vif whereas the EBΔI34
and EBΔ69-72 mutants could still significantly prevents
Wang et al. Retrovirology 2013, 10:94 Page 11 of 16
http://www.retrovirology.com/content/10/1/94degradation of Vif (Figure 7I), indicating that EloB stabi-
lized Vif through residues 9-17. To further explore the
exact site responsible for Vif stabilization, we constructed
three mutants, VR-EBΔ9-11-HA, VR-EBΔ12-14-HA and
VR-EBΔ15-17-HA, and found that the EBΔ9-11 and
EBΔ12-14 mutations had impaired the ability of the mol-
ecule to stabilize Vif; meanwhile, the EBΔ15-17 mutant
could still significantly stabilize Vif (Figure 7J), implying
that EloB stabilizes Vif mainly through residues 9-14
which lies within its UbL domain.
Discussion
EloB (and EloC) plays a role in promoting CBF-β binding
to Vif
A recently discovered component of the Vif-Cul5 E3
complex, CBF-β, was reported to regulate Vif-Cul5 E3
ligase assembly by promoting folding of the N-terminal
region of Vif [33-36], contributing to the Cul5 binding
to Vif [13,33,36], which raised further concerns about
the functions of components of the Vif-CBF-β-Cul5
complex. In an attempt to investigate functions of the
components of the Vif-CBF-β-EloB-EloC-Cul5 E3 ligase,
we failed to knock down EloC effectively. However, with
the successful knockdown of endogenous EloB expres-
sion by using siRNA, it was not surprising to find that
indeed Vif function was impaired (Figure 1). To explore
the mechanism used by EloB to affect Vif function, we
examined the interactions of HIV-1 Vif with its substrate
A3G and its cognate partners, endogenous Cul5, EloB/
EloC and CBF-β, under the condition of EloB silencing.
We found that EloB silencing could reduce Vif binding
to CBF-β and Cul5, whereas binding to A3G did not
seem to be affected (Figure 2). The decrease in Cul5
binding may have been caused by the decline of Vif-
EloC binding and Vif-CBF-β binding, both of which had
been reported to negatively affect Cul5 binding to Vif
[13,33]. Therefore, we considered that EloB might play a
role in influencing the recruitment of CBF-β to Vif.
However, since EloC expression was also reduced by
EloB silencing (Figure 2), we wondered if EloB could
regulate the Vif-CBF-β binding by directly interacting
with Vif (or CBF-β) or simply by down-regulating the
Vif-EloC interaction, or both.
Possible mechanisms used by EloB (and EloC) to facilitate
CBF-β recruitment
By examining the interaction of CBF-β with EloB, we con-
firmed that there was no direct contact between them,
consistent with the experimental results reported by
Zhang et al. [33]. By using a VifΔSLQ mutant, we found
that the Vif-EloC interaction was crucial for CBF-β bind-
ing to Vif. It has been reported that Vif interacts with
CBF-β through its N-terminus, whereas the contact
sites between EloB-EloC and CBF-β are located in itsC-terminus [13,33]. Therefore, EloB and EloC may affect
the recruitment of CBF-β to Vif by inducing a structural
change in Vif. Based on our results, EloB (and EloC) may
use two potential mechanisms to induce a structural
change of Vif. The first one is that EloB induces EloC fold-
ing to facilitate EloC binding to Vif, which would then
induce a structural change in Vif. Alternatively, EloB may
directly induce a structural change of Vif via its C-
terminus, which interacts with the PPLP motif of Vif [26].
However, as reported previously [33], the interaction be-
tween Vif and EloB is dependent on the binding of EloB-
EloC to the BC-box of Vif [33]. To evaluate which of these
explanations would be more plausible, we constructed a
dominant-negative EloB mutant with a deletion of the
C-terminal 34 amino acids, which still retains the ability
to bind EloC but lacks the Vif binding motif (Figure 5)
[26]. We showed that over-expression of the EloBΔC34
mutant (but not the EloBΔC11 mutant, data not shown)
could impair Vif function when E4orf6-mediated deple-
tion of P53 seemed not to be affected (Figure 5). The
over-expressed EloBΔC34 mutant also reduced the inter-
action of Vif with CBF-β (Figure 6). The interaction of
EloC with Vif was not apparently affected in the presence
of EloBΔC34 in our study, implying that the Vif-binding
site of EloB may be important for Vif function and for Vif
to recruit CBF-β. By using a VifΔPPL mutant, we again
found the interaction between Vif and EloB to play a po-
tential role in promoting the Vif-CBF-β interaction, thus
lending greater credence to the latter explanation de-
scribed above. Since the interaction between the Vif PPLP
motif and the EloB C-terminus is reported to be required
for Vif binding to Cul5 [26], we presumed here that EloB
facilitates Vif and Cul5 binding by promoting CBF-β re-
cruitment. However, because the C-terminal 34 amino
acids of EloB contains EloC binding sites (Figure 5A) [71],
we cannot thoroughly rule out the possibility that
EloBΔC34 fails to induce the correct conformation of
EloC, thereby influencing EloC-Vif binding and affecting
the function of Vif.
Based on our results of the co-immunoprecipitation
assays and the analysis of the interaction network of the
Vif-CBF-β-EloB-EloC complex in E. coli, we presumed
that EloC alone may not be able to efficiently interact
with Vif in the absence of EloB, as mentioned by other
researchers previously [74]. In addition, both of the con-
tacts between the Vif BC-box and EloB-EloC and be-
tween the PPLP motif of Vif and the C-terminus of EloB
can induce a structural change in Vif, as well as facilitate
Vif hijacking of cellular CBF-β [26].
EloB stabilizes Vif utilizing the same region by which it
interacts with EloC
Although EloB has previously shown virtually no effect
on VHL stability [58], in this study EloB demonstrated
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was sufficient to confer this ability (Figure 3, Figure 7).
However, we noticed that only over-expression of EloB
(free EloB) could remarkably stabilize Vif, while neither
the co-expression of EloB and EloC (1:1) nor the native
EloB in the cell could result in obvious Vif stabilization
(Figures 3, 5, 7). We presumed that this observation may
be a result of EloB preventing the degradation of Vif
through the same sites by which it interacts with EloC.
Thus, when EloB is expressed at comparable levels to
EloC, it will preferentially form a stable obligate hete-
rodimer with EloC and lose the capacity to markedly
stabilize Vif. This hypothesis was verified by experiments
shown in Figure 7. Since a high intracellular protein level
of HIV-1 Vif has been shown to inhibit viral infectivity
[56], the remarkable stabilization of Vif may also impair
viral infectivity. However, the mechanism by which free
EloB prevents Vif degradation was not determined in
our study.
It is worth noting that stabilization of Vif by EloB had
no obvious effects on Vif activity (Figure 5C). When the
Vif protein level was greatly increased by EloBΔC34
over-expression, its activity was impaired (Figure 5C, E),
suggesting that EloBΔC34 caused a structural aberration
or some other distortion that affected the function of
Vif. In other words, the amount of the dominant-
negative mutant EloBΔC34, which was far in excess of
the endogenous EloC, competitively bound to EloC and
resulted in the failure to induce a functionally active
structure of Vif. This impairment of Vif could be re-
lieved by over-expression of EloC in a dose-dependent
manner (data not shown). These results also indicated
that EloB uses different pathways to stabilize Vif and to
induce structural changes of Vif.
We suspected the possible biological reason in the
finding that free EloB can stabilize Vif, especially if there
is no consequence on its activity. Most small chaperones
could bind transiently to unstructured nascent proteins
and thus prevent their premature folding and aggre-
gation [64,75], assisting the proteolytic system to de-
termine the fate of proteins [76]. Thus, although the
mechanism that free EloB stabilized Vif was not clear,
we supposed that, as a molecular chaperone, free EloB
might help to stabilize an intermediate folding state of
Vif which has no activity, or it might play a role in the
regulation of Vif oligomerization and stabilize a Vif
multimer which has no activity, in both of these cases
over-expressed EloB could ultimately stabilize the Vif
protein level.
We found a weak interaction between the Vif-SLQ
mutant and EloB (Figure 7G) which might exist between
EloB and the N-terminal region of Vif-SLQ (data was
not shown) and result in Vif SLQ stabilization. There
seemed to be some some discrepancy regarding theeffect of the EloB binding on Vif stabilization. The ELoB
interaction with Vif SLQ is much weaker than with wt
Vif (as shown in Figure 7G), why is this mutant stabi-
lized as well or even better than wt Vif? Indeed, wt Vif
was seemed to have a stronger capability to bind EloB
than Vif-SLQ did, but we believe that might be because
wt Vif could stably bind EloC which could interact with
EloB and induce EloB co-immunoprecipitation with Vif
[13]. We could not obtain a complete knockdown of
EloC (data not shown), so we were not able to exclude
the interference of EloC on estimating the direct inter-
action between EloB and the N-terminal region of Vif.
Thus the direct interaction between EloB and Vif might
be comparable with that between EloB and Vif-SLQ,
causing the stabilization event of wt Vif as well as or
even weaker than that of Vif-SLQ.Conclusion
In summary, our results demonstrate that both of the in-
teractions between HIV-1 Vif and human EloB-EloC
(Vif SLQ motif with EloC and Vif PPLP motif with EloB)
are highly important for the recruitment of CBF-β to
Vif. Based on our results, we conclude that EloB can dir-
ectly affect the assembly of the Vif-CBF-β-Cul5 E3 com-
plex as EloC does by interacting with the PPLP motif of
Vif. We identified that the EloB C-terminus, which is
not necessary for EloC binding and for E4orf6-mediated
depletion of P53, may play a role in improving Vif func-
tion. Therefore, the EloB C-terminal tail may be investi-
gated as a promising drug target. Moreover, we found
that over-expressed EloB could remarkably stabilize Vif
mainly though the same region (residues 9-14) it used to
bind EloC. And this important point further expands the
diversity of functions of UbL proteins. Thus, our obser-
vations extend the current understanding of the function
of the Vif-CBF-β-Cul5 E3 ligase.Methods
Plasmids
The polycistronic expression system pST39/pET3aTr
(a generous gift from Song Tan, Pennsylvania State Uni-
versity, University Park, PA) was used to produce the
plasmids pST39-Vif, pST39-EloB, pST39-EloC, pST39-
CBF-β, pST39-Vif-CBF-β, pST39-Vif-EloB, pST39-Vif-
EloC, pST39-Vif-EloB-EloC, pST39-Vif-EloB-CBF-β,
pST39-Vif-EloC-CBF-β and pST39-Vif-EloB-EloC-CBF-
β for expression of proteins or protein complexes in
E. coli. In these plasmids, sequences encoding the fol-
lowing proteins were cloned between the indicated re-
striction sites: Vif, XbaI and BamHI; CBF-β, EcoRI and
HindIII; EloC, SacI and KpnI; and EloB, BspEI and MluI
[63]. The CBF-β gene was acquired by RT-PCR as de-
scribed below.
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EloBΔC34 were generated by subcloning EloB/Flag-EloB
and EloBΔC34/Flag-EloBΔC34 into the VR1012 vector at
the PstI and BamHI restriction sites. VR-Vif-HA, VR-Vif,
VR-VifΔSLQ, VR-Vif-Myc, VR-VifΔSLQ-Myc, VR-EloB-
Myc, VR-EloB-HA, VR-EloC-HA and pcDNA3.1-A3G-HA
have been previously described [13,27,77]. VR-EBΔ9-17-
HA, VR-EBΔI34-HA, VR-EBΔ69-72-HA, VR-EBΔ9-11-
HA, VR-EBΔ12-14-HA and VR-EBΔ15-17-HA were
derived from VR-EloB-HA via site-directed mutagen-
esis. VR-P53-HA and the adenovirus E4orf6 expression
plasmid were generous gifts from Xiao-Fang Yu (Johns
Hopkins University, Baltimore, MD) [73].
The infectious molecular clone pNL4-3ΔVif was ob-
tained from the National Institutes of Health AIDS Re-
search and Reference Reagents Program (NIH-ARRRP),
Division of AIDS, National Institute of Allergy and Infec-
tious Diseases (NIAID) in Germantown, MD.
Cells, antibodies and transfections
HEK293T (CRL-11,268) cells were purchased from the
American Type Culture Collection (ATCC, Manassas,
VA, USA). MAGI-CCR5 cells (catalog no. 3522) were
obtained through the NIH-ARRRP. The cells were
maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum
(FBS) at 37°C and 5% CO2. The following antibodies
were used in this study: anti-HA mouse monoclonal
antibody (mAb) (Covance, Emeryville, CA), anti-Myc
mouse mAb (Millipore, Billerica, MA), anti-Flag mouse
mAb (Sigma–Aldrich, St. Louis, MO, USA), anti-P53
mAb (Santa Cruz Biotechnology, Santa Cruz, CA), anti-
human ribosomal P antigen (Immunovision, Springdale,
AR), anti-tubulin mouse mAb (Covance), anti-Cul5
rabbit polyclonal antibody (pAb) (Santa Cruz Biotech-
nology), anti-ElonginB rabbit pAb (Abcam, Cambridge,
MA), anti-ElonginC (BD Transduction Lab, San Jose,
CA), anti-CBF-β (Santa Cruz Biotechnology), anti-Vif
antibody (NIH-ARRRP, catalog no. 2221) and a mono-
clonal anti-HIV-1 capsid antibody generated from an
HIV-1 p24 hybridoma (NIH-ARRRP) to detect Pr55Gag
and CAp24. Plasmid transfections into 293 T cells
were performed with Lipofectamine 2000 according to
the standard protocol provided by the manufacturer
(Invitrogen, Carlsbad, CA).
RNA interference (RNAi) and qRT-PCR
The following double-stranded siRNAs specific to human
EloB were purchased from Shanghai GenePharma Co., Ltd
(Shanghai, China): EloB-siRNA1 (siEB1), GGGAAGCAG
UGCCAAUGAATT; EloB-siRNA2 (siEB2), UGACCAA
CUCUUGGAUGAUTT; EloB-siRNA3 (siEB3), GACG
AUGGCCAAGAGCAGATT. The AllStars Negative Con-
trol siRNA was obtained from Qiagen (siNC, catalog no.1,027,284, Hilden, Germany). Hiperfect transfection re-
agent (Qiagen) was used for transfection of 293 T cells with
EloB siRNAs at a final concentration of 20 nM according
to the manufacturer’s recommendations (Qiagen). Protein
expression was monitored by immunoblotting 3 days after
transfection. Efficiency of siRNA silencing of EloB was
evaluated both by evaluating relative gene expression using
qRT-PCR and protein expression by Western blot. Total
cellular RNA was isolated from the siRNA-transfected
293 T cells using TRIzol (Invitrogen) and used as the
template in cDNA synthesis with the Promega Reverse
Transcription System (Promega, Madison, WI). qRT-PCR
analysis for EloB and β-actin was performed using the 2×
QuantiTect™ SYBR Green PCR Master Mix (Qiagen),
C1000™ Thermal Cycler (BioRad CFX 96™ Real-Time Sys-
tem, Hercules, CA) and PCR primers for EloB (forward,
CGAACTGAAGCGCATCGTC; reverse, TCCAAGAGT
TGGTCATCCTTGT) and β-actin (forward, AGCGGG
AAATCGTGC; reverse, CAGGGTACATGGTGGTGC).
The cDNA acquired above was also used as the template
for CBF-β amplification using the following primers based
on primers described before [33]: forward (5-’ GGAAT
TCCATATGCCGCGCGTCGTG-3’) and reverse (5’-CGC
GGATCCCTAGGGT CTTGTTGTCTTCTTGC-3’). NdeI
and BamHI restriction sites (in bold) were included in the
primers to facilitate cloning into pET3aTr.
Co-immunoprecipitation assay
At 48 h post-transfection, 293 T cells were harvested,
washed with cold PBS and solubilized in lysis buffer
(50 mM Tris, pH 7.5, 150 mM NaCl, 1% Triton X-100)
plus Complete protease inhibitor cocktail tablets (Roche,
Mannheim, Germany) at 4°C for 1 h. The cell lysates
were clarified by 30 min of centrifugation at 10,000 × g
and then incubated with anti-HA Ab-conjugated agarose
beads (Roche) at 4°C for 3 h. Alternatively, the pre-
clarified lysates were incubated with mouse anti-Myc
(Millipore) for 3 h, and Protein G-agarose was then
added for a 3-h incubation at 4°C. Subsequently, the
samples were washed three times with washing buffer
(20 mM Tris, pH = 7.5, 100 mM NaCl and 0.05% Tween
20), boiled in SDS sample buffer and then analyzed by
SDS-PAGE and immunoblotting.
Virus purification and viral infectivity (MAGI) assay
Virus particles were harvested 48 h after transfection,
and culture supernatants obtained were clarified by cen-
trifugation at 3000 rpm for 10 min and then filtered
through a 0.22-μm pore size membrane. Virions were
pelleted through a 20% sucrose cushion by ultracentrifu-
gation at 26,000 rpm for 2 h at 4°C in a Beckman SW40
rotor. For immunoblotting, virions were disrupted in
radioimmunoprecipitation assay (RIPA) buffer. Virus in-
fectivity was examined by the MAGI assay as described
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and syncytia were counted to determine viral infectivity.
Virus input was normalized by the level of p24.
CHX Vif stability assay
293 T cells were grown to confluence in 6-well culture
dishes. At 36 h post-transfection, cells were treated with
CHX (Sigma–Aldrich) at the final concentration 100 μg/
ml for various time periods, lysed and analyzed by Western
blotting.
Solubility analysis
Individual proteins and protein complexes were expressed
in E. coli BL21 (DE3) cells containing appropriate pST39
constructs. Cells were grown in Luria-Bertani (LB) me-
dium with 50 mg/L ampicillin at 37°C until an optical
density (OD) of about 0.8 was reached. The proteins were
over-expressed at 37°C for 7 h by induction with isopropyl-
D-thiogalactopyranoside (IPTG, 0.5 mM final concentra-
tion). Harvested cells were resuspended in PBS (pH 7.4),
homogenized by sonication and then clarified by centrifu-
gation at 16,000 × g for 1.5 h. For solubility analysis, the
supernatant was carefully removed, and the pellet was
washed with PBS twice and then resuspended in a volume
equal to the original volume of the supernatant.
Western blotting
Cells and viruses were harvested at 48 h post-transfection
and solubilized with RIPA buffer. Samples were boiled in
SDS sample buffer for 20 min, subjected to Tricine-SDS–
PAGE and then transferred onto nitrocellulose membranes
(Whatman, Kent, UK). Secondary antibodies used in this
study were alkaline phosphatase-conjugated affinipure goat
anti-rabbit IgG, goat anti-mouse IgG and goat anti-human
IgG (Jackson Immunoresearch Laboratories, West Grove,
PA). Immunoreactions were detected with 5-bromo-4-
chloro-3-indolylphosphate (BCIP) and nitro blue tetrazo-
lium chloride (NBT) solutions.
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